Juu, on kaksi tapaa poistaa oire. Yrittää poista oireen mahdollinen syy, tai estää oire piilottamalla se. Mutta toki joskus jälkimmäinen on kai sallittua perusteltuakin.

Enpä ole tavannut ihmistä joka ei olisi törmännyt jokapaikassa pursuavaan tulehduskipulääkkeiden mainontaan. Mitähän siitä muuten pidemmän päälle seuraa... olen hivenen huolissani. Mutta toki se huoli ei koske tilapäistä harkittua käyttökertaa.
Maailmalla alkaa kuulua enenevässä määrin:
Tämä oli jostain tupakoivien Norskien jutusta...
"The study was relatively small — 908 people — and involved people prone to heart problems and cancer because they smoked. But specialists said it supports the Food and Drug Administration's recent decision to warn about long-term use of all such painkillers except aspirin.
The findings add to the suspicion that the heart risk extends beyond the so-called cox-2 drugs — Bextra, Vioxx and Celebrex —
to the larger family of medications known as non-steroidal anti-inflammatory drugs, or NSAIDs, which include naproxen, ibuprofen and virtually all other over-the-counter pain relievers except acetaminophen or Tylenol
"
Toisaalla:
Ibuprofen and Heart Attacks
The California study also showed an increased risk of heart attack associated with several older anti-inflammatory drugs, including ibuprofen. That drug appeared to raise the users' risk of heart attack by 11%, an increased risk that Graham referred to as "small but significant" since tens of millions of Americans use the drug regularly.
Other NSAIDs, including indomethacin, a drug often used for gout, and Mobic, an increasingly popular drug since the Cox-2 drugs came under fire, also appeared to raise heart attack risk by 40% to 70%, according to the study.
Graham said the data suggest that researchers must take a closer look at older anti-inflammatory drugs to learn more about their possible safety concerns. Regulators should "weed the garden of bad actors," he said
SOURCES: David Graham, MD, associate director for science and medicine, FDA Office of Drug Safety. Pfizer, Inc. Merck. "